Board of directors (resolutions 4 to 9)
The independence rate of the Board amounts to only 38.5%.
Each of the three largest shareholders should have at least one representative regardless of the board's independence. Accordingly, we recommend that shareholders approve the re-election of Anne Beaufour but not Philippe Bonhomme. A new member, Paul Sekhri, is chairman of two listed companies and member of the Board of two others listed companies. Therefore, we have concerns about his time commitment.
Remuneration (resolutions 10 to 13) The lack of disclosure of the achievement rates of each criterion for the bonus is not acceptable. Performance shares are based on unverifiable criteria and are measured only over a two-year period. Therefore, David Meek does not receive a real long-term remuneration. Finally, quantum is excessive. Therefore, we recommend that shareholders oppose the CEO’s remuneration.
Due to an excessive amount in 2017, we recommend that shareholders oppose the chairman of the Board’s remuneration. For 2018, a decrease of his base salary is due to his new function. Shareholders have interest in approving a new remuneration policy which is less excessive.
Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
We synthesise here the main take-away messages from the annual ESMO congress which took place in Munich in October. We present the conclusions in sections organised by organ with three main parts: renal-cell carcinoma (RCC), breast cancer (BC) and lung cancer (NSCLC) with non-uniform levels of innovation and progress. The last section is dedicated to head & neck cancer with encouraging updated data on monatuximab/cetuxima
In general, Danske Bank is in compliance with the Danish regulations relating to the organisation and procedures of the Extraordinary General Meeting. In light of the money-laundering case at the Company's Estonian branch, which has led to the resignation of several senior executives including Danske Bank's CEO (Mr.Borgen) and Head of Business Banking (Mr. Morch), major shareholder A.P. Moller Holding proposes changes to the board of directors. Under ITEM 1.1, major shareholder A.P. Moller Holding proposes to newly appoint Mr.Dybvad as Member of the board of directors. Based on the available...
La société propose à ses actionnaires de changer son mode d'administration afin de passer à une structure moniste. Si ce changement seul ne semble pas poser particulièrement de problème, cependant la société n’explique pas clairement les objectifs de ce changement, ni même si les fonctions de Directeur Général et de Président du conseil vont continuer à être séparées. Par ailleurs le manque de transparence sur les rémunérations engendra une recommandation de vote négatif pour les résolutions 6 à 10 et de 27 à 28.
Suite à la finalisation de l'OPA qu'il a lancé en novembre 2017, Schneider Electric devient actionnaire majoritaire d'IGE+XAO, avec 70,89% du capital et 61,86% des droits de vote. Par ailleurs, le Conseil d'Administration fait lui l'objet de quelques changements notamment suite au départ de 3 administrateurs au profit de 4 nouveaux administrateurs occupant des postes au sein de Schneider Electric.
La Société soumet à l’approbation des actionnaires, comme l’impose la Loi Sapin 2, la politique de rémunération des mandataires sociaux dirigeants. Bien que la Société communique les éléments de la rémunération du Président-Directeur Général (à l'exception des montants) pour le nouvel exercice et la rémunération attribuée au titre de l’exercice 2017, aucune information relative à celle du Directeur Général, soumise à l’approbation n’est pour autant communiquée (résolutions 7 à 9). Proxinvest ne soutiendra pas les résolutions relatives aux augmentations de capital, considérant que leur maintie...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.